The field of sleep pharmacology is dynamic in nature and rapid advances are occurring in the field. For example, screening for new drug candidates, development of new drugs, identification of molecular targets, and works related to its efficacy and safety profiles. Furthermore, this leads to the development of evidence-based therapeutic guidelines. Insomnia Disorder: Epidemiology, Causes, and Pharmacotherapy consolidates the latest developments into one volume. It provides the latest, up-to-date knowledge regarding sleep and sleep therapeutics for sleep physicians, sleep researchers, psychiatrists, and any medical professional interested in the interdisciplinary areas of sleep therapeutics. Chapters include topics such as neurobiology, neurotransmitters, regulation of sleep and wakefulness, and overview of all current pharmacotherapies for insomnia.
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science Publishing Co Inc
Zielgruppe
Produkt-Hinweis
Broschur/Paperback
Klebebindung
Maße
Höhe: 229 mm
Breite: 152 mm
ISBN-13
978-0-12-823412-9 (9780128234129)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
Jaime M. Monti is Professor, Department of Pharmacology and Therapeutics, School of Medicine, Clinics Hospital, University of the Republic, Uruguay. He is a member of the International College of Neuropsychopharmacology, Sleep Research Society (USA), European Sleep Research Society, and the Argentinian Society of Sleep Medicine. S.R. Pandi-Perumal, MSc is the President and Chief Executive Officer of Somnogen Canada Inc., a Canadian corporation. Pandi is popular among the sleep community. He is a world-acclaimed sleep researcher and has authored over 300 publications and has edited over 25 high-profile academic volumes dealing with various sleep-related topics. His name is also on the list of the top 2% of scientists in the world, compiled by Stanford University, Elsevier, and SciTech Strategies. Drawn to the benefits and significance of the sleep cycle, his personal and professional careers have been involved in advocating/achieving a good night's slumber. Further details about the editor can be viewed at https://pandi-perumal.blogspot.com.
Herausgeber*in
Professor, Department of Pharmacology and Therapeutics, School of Medicine, Clinics Hospital, University of the Republic, Uruguay
President and Chief Executive Officer, Somnogen Canada Inc, Canada
1. Neurobiology of sleep and waking
2. Neurotransmitters and sleep
3. Regulation of sleep and wakefulness (two-process model of sleep and three-process model of alertness)3. Chronobiotics and chronohypnotics
4. Normal sleep in children adolescents, adults, and older adults
5. Insomnia: Overview and classification
6. Insomnia characteristics in children, adolescents, adults, and older adults
7. Mechanism of action of presently available hypnotic drugs
8. Pharmacokinetics of presently available hypnotic drugs
9. Non-pharmacological treatment of an insomnia disorder
10. Benzodiazepine hypnotics
11. "Zeta drugs": Zopiclone, Eszopiclone, Zolpidem, and Zaleplon
12. Melatonin and melatonin receptor agonists (Ramelteon, Tasimelteon)
13. Histamine H1 receptor antagonists (with special emphasis on low-dose Doxepin)
14. Orexin receptor antagonists (Suvorexant, Lemborexant)
15. Insomnia and CAM therapies: an evidence-based approach
